Hyloris Takes Maxigesic IV To South Korea And Panama
As Company Makes Progress With Regulatory Submission Process In US
• By Akriti Seth
After expanding the footprint of Maxigesic IV in several European countries, Hyloris has now received regulatory approvals for the non-opioid post-operative pain treatment in South Korea and Panama. The company remains focused on increasing the global footprint of Maxigesic IV in other countries, including the US.
Mayne Pharma markets more than twenty dermatology products in the US • Source: Alamy
Belgian value-added medicines specialist Hyloris Pharmaceuticals SA has announced receiving regulatory approvals for its Maxigesic IV (paracetamol/ibuprofen) 1,000mg/300mg non-opioid treatment for post-operative pain in South Korea and Panama.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
